FI964332A - Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen - Google Patents

Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen Download PDF

Info

Publication number
FI964332A
FI964332A FI964332A FI964332A FI964332A FI 964332 A FI964332 A FI 964332A FI 964332 A FI964332 A FI 964332A FI 964332 A FI964332 A FI 964332A FI 964332 A FI964332 A FI 964332A
Authority
FI
Finland
Prior art keywords
prosthesis
acid derivatives
pct
migration
loosening
Prior art date
Application number
FI964332A
Other languages
English (en)
Swedish (sv)
Other versions
FI118590B (fi
FI964332A0 (fi
Inventor
Allen E Goodship
John Kenwright
Jonathan Green
Original Assignee
Ciba Geigy Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ciba Geigy Ag filed Critical Ciba Geigy Ag
Publication of FI964332A publication Critical patent/FI964332A/fi
Publication of FI964332A0 publication Critical patent/FI964332A0/fi
Application granted granted Critical
Publication of FI118590B publication Critical patent/FI118590B/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Chemical Treatment Of Metals (AREA)
  • Dental Preparations (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
FI964332A 1994-05-04 1996-10-28 1-hydroksi -2- (imidatsol -1-yyli) etaani -1,1 -difosfonihapon käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen FI118590B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB9408775 1994-05-04
GB9408775A GB9408775D0 (en) 1994-05-04 1994-05-04 Use of certain methanebisphosphonic acid derivatives to prevent prothesis loosening and prothesis migration
IB9500288 1995-04-24
PCT/IB1995/000288 WO1995030421A1 (en) 1994-05-04 1995-04-24 Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration

Publications (3)

Publication Number Publication Date
FI964332A true FI964332A (fi) 1996-10-28
FI964332A0 FI964332A0 (fi) 1996-10-28
FI118590B FI118590B (fi) 2008-01-15

Family

ID=10754497

Family Applications (1)

Application Number Title Priority Date Filing Date
FI964332A FI118590B (fi) 1994-05-04 1996-10-28 1-hydroksi -2- (imidatsol -1-yyli) etaani -1,1 -difosfonihapon käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen

Country Status (18)

Country Link
US (1) US5965547A (fi)
EP (1) EP0758241B1 (fi)
JP (1) JPH09512816A (fi)
AT (1) ATE218350T1 (fi)
AU (1) AU693541B2 (fi)
DE (1) DE69526937T2 (fi)
DK (1) DK0758241T3 (fi)
ES (1) ES2177642T3 (fi)
FI (1) FI118590B (fi)
GB (1) GB9408775D0 (fi)
HU (1) HUT74984A (fi)
IL (1) IL113566A (fi)
NO (1) NO310057B1 (fi)
NZ (1) NZ283430A (fi)
PT (1) PT758241E (fi)
TW (1) TW458779B (fi)
WO (1) WO1995030421A1 (fi)
ZA (1) ZA953537B (fi)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices
US6117856A (en) * 1996-02-14 2000-09-12 Binderman; Itzhak Topical bisphosphonates for prevention of bone resorption
US5994329A (en) 1997-07-22 1999-11-30 Merck & Co., Inc. Method for inhibiting bone resorption
US6432932B1 (en) 1997-07-22 2002-08-13 Merck & Co., Inc. Method for inhibiting bone resorption
GB2336311A (en) * 1998-04-15 1999-10-20 Merck & Co Inc Bisphosphonate Dosing Regimen
US6137012A (en) 1998-10-13 2000-10-24 E. I. Du Pont De Nemours And Company Phosphole and diphosphole ligands for catalysis
JP3793023B2 (ja) 1998-12-04 2006-07-05 ロシュ ダイアグノスティックス ゲーエムベーハー 体内プロテーゼの骨統合を促進するためのイバンドロネートの使用
JP2002536123A (ja) * 1999-02-09 2002-10-29 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ 抗吸収性骨セメントならびに同種、自家、および異種骨移植片
WO2001008690A1 (fr) * 1999-08-02 2001-02-08 Toray Industries, Inc. Stabilisateurs d'insertion pour implants
AUPQ232599A0 (en) * 1999-08-19 1999-09-09 Royal Alexandra Hospital For Children, The Drug for treating fractures
EP1591122B1 (en) 2000-06-20 2012-09-26 Novartis AG Method of administering bisphosphonates
EP1296689B3 (en) * 2000-06-20 2013-02-13 Novartis AG Method of administering bisphosphonates
WO2002004038A1 (en) * 2000-07-12 2002-01-17 Hopital Orthopedique De La Suisse Romande Active biocoating for bone implant
GB0029111D0 (en) * 2000-11-29 2001-01-10 Novartis Ag Organic compounds
CA2372450A1 (en) * 2001-05-10 2001-09-19 Pharmaceutical Partners Of Canada Inc. Liquid injectable formulation of disodium pamidronate
MXPA04009586A (es) * 2002-05-10 2005-01-11 Hoffmann La Roche Acidos bisfosfonicos para el tratamiento y prevencion de la osteoporosis.
TWI344367B (en) * 2002-09-16 2011-07-01 Novartis Ag Use of zoledronic acid or a pharmaceutically acceptable salt or hydrate thereof in the preparation of a medicament for the treatment of osteoporosis post hip fracture
US20040138180A1 (en) * 2002-10-03 2004-07-15 Barr Laboratories, Inc. Bisphosphonate composition and process for the preparation thereof
US8071574B2 (en) * 2005-02-22 2011-12-06 John Dennis Bobyn Implant improving local bone formation
JP2010510195A (ja) * 2006-11-17 2010-04-02 ベシンズ・ヘルスケアー ビスホスホネート化合物を含む液体薬剤組成物
EP1958649A1 (en) * 2007-02-14 2008-08-20 Graftys Injectable calcium-phosphate cement releasing a bone resorption inhibitor
US20100144679A1 (en) * 2007-03-21 2010-06-10 Duke University Medication kits and formulations for preventing, treating or reducing secondary fractures after previous fracture
WO2008152518A2 (en) * 2007-05-16 2008-12-18 Actavis Group Ptc Ehf Process for the preparation of risedronic acid or risedronate sodium
CN102639137A (zh) 2009-09-01 2012-08-15 杜克大学 双膦酸类组合物及其治疗心力衰竭的方法
US8882740B2 (en) * 2009-12-23 2014-11-11 Stryker Trauma Gmbh Method of delivering a biphosphonate and/or strontium ranelate below the surface of a bone
JP6261512B2 (ja) 2011-11-16 2018-01-17 デューク ユニバーシティ 心機能障害を治療及び／又は低減するためのビスホスホネート組成物並びに方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2405254C2 (de) * 1974-02-04 1982-05-27 Henkel KGaA, 4000 Düsseldorf Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper
US4639338A (en) * 1984-08-06 1987-01-27 Ciba-Geigy Corporation Preparation of crystalline disodium 3-amino-1-hydroxypropane-1,1-diphosphonate pentahydrate
EP0275821B1 (de) * 1986-11-21 1992-02-26 Ciba-Geigy Ag Neue substituierte Alkandiphosphonsäuren
JPH05163150A (ja) * 1991-05-13 1993-06-29 E R Squibb & Sons Inc アテローム性動脈硬化症の抑制・治療剤
US5403829A (en) * 1993-03-24 1995-04-04 Leiras Oy Use of bisphosphonates in endo-osteal bone surgery
US5646134A (en) * 1994-04-21 1997-07-08 Merck & Co., Inc. Alendronate therapy to prevent loosening of, or pain associated with, orthopedic implant devices

Also Published As

Publication number Publication date
US5965547A (en) 1999-10-12
ATE218350T1 (de) 2002-06-15
HUT74984A (en) 1997-03-28
EP0758241A1 (en) 1997-02-19
NO964486D0 (no) 1996-10-22
ES2177642T3 (es) 2002-12-16
GB9408775D0 (en) 1994-06-22
NO964486L (no) 1996-10-22
DE69526937T2 (de) 2003-01-02
AU693541B2 (en) 1998-07-02
FI118590B (fi) 2008-01-15
JPH09512816A (ja) 1997-12-22
NZ283430A (en) 2000-06-23
IL113566A (en) 2002-05-23
DE69526937D1 (de) 2002-07-11
PT758241E (pt) 2002-10-31
IL113566A0 (en) 1995-08-31
TW458779B (en) 2001-10-11
AU2146695A (en) 1995-11-29
WO1995030421A1 (en) 1995-11-16
EP0758241B1 (en) 2002-06-05
ZA953537B (en) 1995-11-06
FI964332A0 (fi) 1996-10-28
HU9603042D0 (en) 1997-01-28
DK0758241T3 (da) 2002-09-23
NO310057B1 (no) 2001-05-14

Similar Documents

Publication Publication Date Title
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
DE69326776D1 (de) Verwendung von n-arylmethylen ethylendiamintriacetate, n-arylmethylen iminodiacetat oder n,n'-diarylmethylen ethylendiamindiacetat gegen oxidativen stress
BG101118A (en) Therapeutical compounds
ATE141792T1 (de) Verwendung von carbamazepine und oxcarbazepine zur behandlung von parkinson und den parkinson- syndromen
ATE226436T1 (de) Neue verwendung von dexmedetomidin
FI972308A (fi) 2-substituoituja 1,2,5-tiadiatsolidin-3-oni-1,1-dioksideja ja niitä sisältäviä koostumuksia ja menetelmiä niiden käyttämiseksi
PT888327E (pt) Derivados de benzopirano que possuem uma accao antagonistica dos leucotrienos
FI972434A (fi) Lamotrigiiniä sisältävä farmaseuttinen koostumus
IT1282736B1 (it) Uso di derivati del p-amminofenolo per preparare composizioni farmaceutiche utili nel trattamento di malattie neurodegenerative
EE9700366A (et) Angiotensiini II tüüp 1 retseptori antagonistide kasutamine düspeptiliste sümptomite profülaktikas ja/või ravis kasutatava ravimi valmistamiseks ja angiotensiini II tüüp 1 retseptori antagoniste sisaldavad ravimpreparaadid
GR3034142T3 (en) Composition for the treatment or prevention of herpes
MX9605327A (es) Uso de ciertos derivados de acido metanbisfosfonico para prevenir el aflojamiento de las protesis y la emigracion de las protesis.
IL108283A0 (en) Use of riluzole for promoting restoration following radiation
CA2183764A1 (en) Use of certain methanebisphosphonic acid derivatives to prevent prosthesis loosening and prosthesis migration

Legal Events

Date Code Title Description
GB Transfer or assigment of application

Owner name: NOVARTIS AG

FG Patent granted

Ref document number: 118590

Country of ref document: FI